Skip to main content
72 search results for:

Sjögren’s syndrome 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-11-2022 | ACR 2022 | Conference coverage | Article

    LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome

    Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

  2. 29-11-2022 | Gout | News | Article

    The metabolic syndrome may influence the risk for gout

    The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

  3. 15-06-2022 | COVID-19 | Adis Journal Club | Article
    Rheumatology and Therapy

    Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19

    Authors: Federico Boggio, Alessandro Ciavarella, Sara Arcudi, Roberta Gualtierotti, Raffaella Rossio, Francesco Tafuri, Andrea Artoni & Flora Peyvandi Abstract Thrombocytopenia is a common feature of antiphospholipid syndrome (APS) and rarely requires treatment.

  4. 06-04-2022 | Sjögren’s syndrome | News | Article
    News in brief

    Baricitinib warrants further investigation for primary Sjögren’s syndrome

    Findings from a phase 1/2 pilot study suggest that baricitinib may be a promising treatment option for primary Sjögren's syndrome.

  5. 11-04-2022 | Rheumatoid arthritis | News | Article

    Biologic choice has minimal impact on acute coronary syndrome risk in RA

    People with rheumatoid arthritis have a significantly increased risk for acute coronary syndrome that generally does not vary according to which biologic DMARD they are taking, show data from four Nordic countries.

  6. 09-01-2022 | Antiphospholipid syndrome | Adis Journal Club | Article
    Rheumatology and Therapy

    Primary Antiphospholipid Syndrome with and Without Acute Myocardial Infarction/Angina: A Cross-Sectional Study

    Authors: Jozélio Freire de Carvalho & Carlos Ewerton Maia Rodrigues Abstract Introduction Acute myocardial infarct/angina (AMI-A) is a possible complication in primary antiphospholipid syndrome (pAPS) patients.

  7. 08-11-2021 | ACR 2021 | Conference coverage | Article

    Positive phase 2b results for ianalumab in primary Sjögren’s syndrome

    Extended phase 2b follow-up data show that ianalumab is well tolerated for at least 1 year in people with primary Sjögren’s syndrome, and prolonging treatment beyond 6 months leads to further improvements in efficacy outcomes.

  8. 31-08-2021 | Sjögren’s syndrome | News | Article

    Early-onset primary Sjögren’s syndrome linked to more severe disease

    People who develop early-onset primary Sjögren’s syndrome have “strikingly more severe disease activity” and greater activation of the cellular immune system compared with those diagnosed at a later age, researchers report.

  9. 16-06-2021 | Pediatric | News | Article

    Biomarkers may distinguish hyperinflammatory syndromes in children

    She explains that although conditions such as macrophage activation syndrome (MAS), primary hemophagocytic lymphohistiocytosis (HLH), and secondary HLH “share clinical features, they require different treatments,” and “additional diagnostic tools are needed to guide clinical decision making.”

  10. 05-06-2021 | EULAR 2021 | Conference coverage | Article

    Machine learning algorithm could predict COVID-19 acute respiratory distress syndrome

    Researchers have identified a machine learning algorithm that could accurately detect COVID-19 acute respiratory distress syndrome (ARDS) in patients with rheumatic diseases.

  11. 04-06-2021 | EULAR 2021 | Conference coverage | Article

    Promise for belimumab, rituximab combination in patients with primary Sjögren's syndrome

    Subcutaneous belimumab combined with intravenous rituximab is well tolerated by patients with primary Sjögren's syndrome and shows positive signs of efficacy, suggest phase 2 study results.

  12. 29-06-2021 | MIS-C | News | Article

    US survey suggests low rates of multisystem inflammatory syndrome in children with COVID-19

    US estimates suggest that 0.03% of SARS-CoV-2 infections lead to multisystem inflammatory syndrome in children, but rates vary by age and race/ethnicity, shows a report published in JAMA Network Open .

  13. 27-11-2020 | Sjögren’s syndrome | News | Article
    News in brief

    No clinical benefit of abatacept in primary Sjögren’s syndrome

    Phase 3 trial results indicate that abatacept does not have significant clinical efficacy in patients with moderate-to-severe active primary Sjögren’s syndrome.

  14. 08-12-2020 | Sjögren’s syndrome | News | Article
    News in brief

    IL-6 ‘not a relevant therapeutic target’ in primary Sjögren’s syndrome

    Treatment with the IL-6 receptor inhibitor tocilizumab does not improve clinical outcomes for patients with primary Sjögren’s syndrome, suggest findings from the ETAP trial.

  15. 06-10-2020 | Sjögren’s syndrome | News | Article

    Seletalisib may deserve further exploration in primary Sjögren’s syndrome

    Treatment with the selective PI3K-delta inhibitor seletalisib may reduce disease activity in patients with moderate-to-severe primary Sjögren’s syndrome, suggest data from a phase 2 proof-of-concept study.

  16. 13-11-2019 | Behçet’s disease | ACR/ARP 2019 | Article

    Apremilast reduces oral ulcer burden in Behçet’s syndrome

    The small molecule phosphodiesterase 4 inhibitor apremilast reduces the number of oral ulcers and improves quality of life to a greater degree than placebo in people with Behçet’s syndrome, results of the phase III RELIEF study show.

  17. 22-07-2020 | COVID-19 | News | Article

    Promising results with glucocorticoids, tocilizumab for COVID-19-associated cytokine storm syndrome

    Treatment with high-dose methylprednisolone, followed by the interleukin-6 inhibitor tocilizumab if needed, may improve outcomes for patients with COVID-19 and cytokine storm syndrome, suggest findings from the CHIC study published in the Annals of the Rheumatic Diseases .

  18. 29-01-2020 | Sjögren’s syndrome | News | Article

    Iscalimab shows potential for primary Sjögren’s syndrome

    Findings from a phase 2 trial suggest that iscalimab, an anti-CD40 antibody that blocks the CD40–CD154 pathway, warrants further investigation as a treatment option for primary Sjögren’s syndrome.

  19. 06-04-2020 | Sjögren’s syndrome | News | Article

    Support for further study of leflunomide–hydroxychloroquine for primary Sjögren’s syndrome

    Findings from RepurpSS-I, a small phase 2a trial, suggest that leflunomide–hydroxychloroquine combination therapy has a favorable safety profile and gives rise to a clinical response in patients with primary Sjögren’s syndrome.

  20. 05-11-2019 | Sjögren’s syndrome | News | Article
    guidelinesWatch

    EULAR releases recommendations for managing Sjögren’s syndrome

    EULAR has issued recommendations for the management of Sjögren’s syndrome with topical and systemic treatments.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.